Jump to content

New CT enrolling now- Atezolizumab (Stage IV Squamous)


Recommended Posts

HI All,

Here is information on two new clinical trials that are recruiting.  Please feel free to share this link to make others aware! 



Currently Recruiting for these two Atezolizumab Trials:

IMpower 110 (GO29431):

A Comparative Study of Atezolizumab With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

This randomized, open-label study will evaluate the safety and efficacy of Atezolizumab compared with treatment with a platinum-based regimen (carboplatin or cisplatin per investigator discretion) + pemetrexed in PD-L1-selected, chemotherapy-naive patients with Stage IV NSCLC.


IMpower 111 (GO29432):

A Study of Atezolizumab Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer.

This randomized, open-label study is designed to evaluate and compare the safety and efficacy of Atezolizumab compared with treatment with gemcitabine + cisplatin or carboplatin in patients with chemotherapy-naive, Stage IV squamous non-small cell lung cancer (NSCLC).

For information about the trials online:  http://www.antipdl1clinicaltrials.com/hcp/antiPDL1_clinical_trial_info/lung-cancer


To Contact the Genentech Trial Information Support Line:


Phone: 1-888-662-6728  (US and Canada only)
Hours of Operation: 6am - 3pm PST Monday – Friday

Email Address: [email protected]

Arin Assero

Senior Director, Global Stakeholder Relations

Cullari Communications Global

[email protected]


Link to post
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...